Stoke Therapeutics’ (STOK) Buy Rating Reiterated at Chardan Capital

Chardan Capital reissued their buy rating on shares of Stoke Therapeutics (NASDAQ:STOK) in a research report report published on Tuesday morning,Benzinga reports. The firm currently has a $35.00 target price on the stock.

STOK has been the topic of several other research reports. BTIG Research reiterated a “buy” rating and set a $39.00 price target on shares of Stoke Therapeutics in a research report on Monday, May 11th. Weiss Ratings lowered Stoke Therapeutics from a “hold (c)” rating to a “sell (d)” rating in a research note on Monday, May 11th. Finally, The Goldman Sachs Group started coverage on Stoke Therapeutics in a report on Monday, July 13th. They set a “buy” rating and a $44.00 price target for the company. Nine investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $43.00.

Stoke Therapeutics Price Performance

STOK stock opened at $31.93 on Tuesday. The company has a market cap of $2.06 billion, a PE ratio of -9.56 and a beta of 1.20. The business has a 50-day simple moving average of $30.41 and a 200 day simple moving average of $32.05. Stoke Therapeutics has a 52 week low of $12.86 and a 52 week high of $40.22.

Stoke Therapeutics (NASDAQ:STOK) last announced its quarterly earnings data on Monday, August 3rd. The company reported ($0.93) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.13). Stoke Therapeutics had a negative return on equity of 59.36% and a negative net margin of 753.60%.The firm had revenue of $9.32 million for the quarter, compared to analyst estimates of $4.89 million. On average, analysts anticipate that Stoke Therapeutics will post -3.41 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, insider Barry Ticho sold 7,176 shares of the firm’s stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $29.04, for a total transaction of $208,391.04. Following the completion of the transaction, the insider directly owned 20,422 shares of the company’s stock, valued at $593,054.88. This trade represents a 26.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, General Counsel Jonathan Allan sold 1,457 shares of Stoke Therapeutics stock in a transaction dated Tuesday, June 16th. The stock was sold at an average price of $29.95, for a total value of $43,637.15. Following the transaction, the general counsel directly owned 18,086 shares in the company, valued at $541,675.70. The trade was a 7.46% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 10,428 shares of company stock worth $306,919. 9.60% of the stock is owned by company insiders.

Institutional Investors Weigh In On Stoke Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in STOK. Hussman Strategic Advisors Inc. acquired a new position in Stoke Therapeutics in the fourth quarter valued at $2,000,000. Baillie Gifford & Co. acquired a new stake in shares of Stoke Therapeutics during the 4th quarter worth approximately $7,837,000. Dimensional Fund Advisors LP grew its position in shares of Stoke Therapeutics by 19.7% during the 1st quarter. Dimensional Fund Advisors LP now owns 989,936 shares of the company’s stock worth $32,229,000 after buying an additional 162,797 shares during the period. Janus Henderson Group PLC increased its stake in shares of Stoke Therapeutics by 11.2% in the 1st quarter. Janus Henderson Group PLC now owns 1,612,781 shares of the company’s stock valued at $52,456,000 after acquiring an additional 161,848 shares in the last quarter. Finally, Candriam S.C.A. lifted its position in shares of Stoke Therapeutics by 12.4% during the 1st quarter. Candriam S.C.A. now owns 502,020 shares of the company’s stock valued at $16,346,000 after acquiring an additional 55,330 shares during the period.

Key Stoke Therapeutics News

Here are the key news stories impacting Stoke Therapeutics this week:

• Positive Sentiment: Wedbush raised its price target to $40 and maintained an “outperform” rating, while Chardan Capital reiterated “buy” with a $35 target. Canaccord retained a “buy” rating despite lowering its target to $58. The broader analyst consensus remains “Moderate Buy,” with an average target of $43. Wedbush price-target update
• Positive Sentiment: Investors continue to focus on Stoke’s pipeline. Management plans to submit a rolling NDA for zorevunersen in the first quarter of 2027 for SCN1A-related Dravet syndrome, while continuing development of STK-002. Approximately $420 million in cash could support these programs and potential launch preparations. Pipeline and NDA outlook
• Neutral Sentiment: Stoke is scheduled to present at the Canaccord Genuity 46th Annual Growth Conference, giving management an opportunity to provide updates on its clinical and regulatory plans. Conference presentation announcement
• Negative Sentiment: HC Wainwright cut its EPS forecasts across 2026–2028: FY2026 to a loss of $3.35 per share from $3.09, FY2027 to a loss of $2.55 from $2.05, and FY2028 to a loss of $1.78 from $0.67. It also lowered quarterly estimates to losses of $0.81 per share. These revisions point to slower progress toward profitability. HC Wainwright earnings estimates
• Negative Sentiment: Stoke’s second-quarter loss of $0.93 per share exceeded the expected loss of $0.80, although revenue of approximately $9.33 million surpassed estimates. The company remains deeply unprofitable, increasing investor sensitivity to cash use and development execution. Second-quarter earnings summary
• Negative Sentiment: Director Barry Ticho sold 7,176 shares for approximately $208,000, reducing his stake by 26%. The sale was conducted under a pre-arranged Rule 10b5-1 plan, which limits its significance but may still weigh modestly on sentiment. SEC insider-sale filing

About Stoke Therapeutics

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.